Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice

References

• Vasen HF. Review article: the Lynch syndrome (hereditary nonpolyposis colorectal cancer). Aliment Pharmacol Ther. 2007;26 Suppl 2:113–126.
   PubMed Web of Science ®Google Scholar
• Barrow E, Hill J, Evans DG. Cancer risk in Lynch syndrome. Fam Cancer. 2013;12:229–240.
   PubMed Web of Science ®Google Scholar
• Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64:430–433.
   PubMed Web of Science ®Google Scholar
• Liu B, Parsons R, Papadopoulos N, et al. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med. 1996;2:169–174.
   PubMed Web of Science ®Google Scholar
• Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition – update of ICG-HNPCC/INSiGHT mutation database. Dis Mark. 2004;20:269–276.
   PubMed Web of Science ®Google Scholar
• Hendriks Y, Franken P, Dierssen JW, et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol. 2003;162:469–477.
   PubMed Web of Science ®Google Scholar
• de Jong AE, van Puijenbroek M, Hendriks Y, et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:972–980.
   PubMed Web of Science ®Google Scholar
• Bonnet D, Selves J, Toulas C, et al. Simplified identification of Lynch syndrome: a prospective, multicenter study. Dig Liver Dis. 2012;44:515–522.
   PubMedGoogle Scholar
• Niv Y. Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer. WJG. 2007;13:1767–1769.
   PubMed Web of Science ®Google Scholar
• Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–834.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89:1758–1762.
   PubMedGoogle Scholar
• Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–268.
   PubMed Web of Science ®Google Scholar
• Sie AS, Mensenkamp AR, Adang EM, et al. Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. Ann Oncol. 2014;25:2001–2007.
   PubMed Web of Science ®Google Scholar
• Vasen HF, Abdirahman M, Brohet R, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology. 2010;138:2300–2306.
   PubMed Web of Science ®Google Scholar
• Vasen HF, de Vos tot Nederveen Cappel WH. Cancer: Lynch syndrome – how should colorectal cancer be managed? Nat Rev Gastroenterol Hepatol. 2011;8:184–186.
   PubMed Web of Science ®Google Scholar
• Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62:812–823.
   PubMed Web of Science ®Google Scholar
• de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut. 2003;52:1752–1755.
   PubMed Web of Science ®Google Scholar
• Natarajan N, Watson P, Silva-Lopez E, et al. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum. 2010;53:77–82.
   PubMed Web of Science ®Google Scholar
• Karlitz JJ, Hsieh MC, Liu Y, et al. Population-based Lynch syndrome screening by microsatellite instability in patients </=50: prevalence, testing determinants, and result availability prior to colon surgery. Am J Gastroenterol. 2015;110:948–955.
   PubMed Web of Science ®Google Scholar
• Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–2087.e3.
   PubMed Web of Science ®Google Scholar
• Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–257.
   PubMed Web of Science ®Google Scholar
• Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut. 2006;55:848–855.
   PubMed Web of Science ®Google Scholar
• He EY, Hawkins NJ, Mak G, et al. The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: an Australian Population-Based Multicenter Study. Oncologist. 2016;21:618–625.
   PubMed Web of Science ®Google Scholar
• Boland CR, Lynch HT. The history of Lynch syndrome. Fam Cancer. 2013;12:145–157.
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr, Le DT. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;373:1979.
   PubMed Web of Science ®Google Scholar
• Promega Corporation. MSI analysis system, version 1.2: technical manual. 08/14;TM255. Available from: www.promega.com
   Google Scholar
• Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998;95:6870–6875.
   PubMed Web of Science ®Google Scholar
• Serrano M, Lage P, Belga S, et al. Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome. Fam Cancer. 2012;11:571–578.
   PubMed Web of Science ®Google Scholar
• Irons RF, Contine KM, Horte JJ, et al. Success of referral to genetic counseling after positive Lynch syndrome screening test. Int J Colorectal Dis. 2017; 32:1345–1348.
   PubMed Web of Science ®Google Scholar
• Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers – the advantage of more extensive colon surgery. Gut. 2011;60:950–957.
   PubMed Web of Science ®Google Scholar
• Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer. 2009;45:365–373.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. JCO. 2010;28:3219–3226.
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;7:19.
   Google Scholar